The World’s First Autonomous Blood Drawing Device

Informacje na temat projektu

VD-1

Identyfikator umowy o grant: 190176843

DOI

10.3030/190176843

Projekt został zamknięty

Data podpisania przez KE 14 Lipca 2023

Data rozpoczęcia 1 Czerwca 2023

Data zakończenia 28 Lutego 2025

Finansowanie w ramach

• The European Innovation Council (EIC)

Koszt całkowity

€ 2 975 301,25

Wkład UE

€ 2 082 710,88

Koordynowany przez

VITESTRO BV
Netherlands

Periodic Reporting for period 2 - VD-1 (The World’s First Autonomous Blood Drawing Device)

Okres sprawozdawczy: 2024-04-01 do 2025-02-28

Podsumowanie kontekstu i ogólnych celów projektu

Vitestro has created the first fully-autonomous device that draws blood from patients. Our solution, called VD-1, performs the whole
venipuncture procedure, from vein detection to bandage application, without any human intervention. We have fully developed our
technology in-house and protected it with seven patents. More than 2,500 patients have tried our solution: the user acceptance, first-time
success rate, and hemolysis rate are comparable to those measured using human nurses. The VD-1 will mitigate the chronic shortage
of healthcare personnel. It will also standardize the venipuncture process, which has been substantially unchanged for decades. We target
two categories of customers – lab chains and hospital labs – and we have launching customers in both of them. Vitestro has a team of
over 70 people, including technical, medical, regulatory, and commercial expertise.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

- We worked on the A.D.O.P.T. Trial, which is the largest trial in autonomous blood drawing worldwide.
- We enrolled the first 1,400 patients in 4 European Hospital Laboratory sites.
- We have completed the technology objectives, increase safety and performance and preparing the device for industrialization.
- We have solved multiple technical challenges in integration of hardware and software.
- We have obtained CE marking and can thereby sell the device within the EU.
- We have placed the first two devices in a commercial setting in the OLVG hospital in Amsterdam

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

- We have raised a Series A-1 funding round of €20M with a consortium of multiple EU and U.S. partners, including EIC Fund
- We have presented trial results at Dutch congress NVKC as well as NVML
- We have signed contracts with 5 different customers for a total of 13 devices
- We have grown the team from 50 to ~100 people
- We have participated as a semi-finalist in the ADLM Disruptive Innovation Award
- We have a total of nine patents filed on all essential parts of the device